Hexal Ag

Hexal Pharma Gmbh

Karin Klokkers

Wilfried Fischer

Ralf Kibele

Anna Sendl-Lang

Daniel Bracher

Hans-Jürgen Schlüter

Brigitte Freudensprung

Hans-Juergen Schlueter

Ina Elfriede Otto

Heidemarie Edith Elfriede Meyer

Andreas Struengmann

Renate Oppelt

Marion Kutschera

The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.

Granulate comprising an oily substance, corresponding production method and tablet

Covering material

The invention relates to a pharmaceutical preparation which consists of or contains cyclosporin A, an emulsifying &agr;-tocopherol derivative, an ethoxylation product of vegetable oils, fatty acids or fats as a further emulsifier and a pharmaceutically customary alcohol.

Pharmaceutical preparation with cyclosporin A

A transdermal patch contains an active loratidine metabolite contained with polyacrylate polymer matrix. The transdermal patch provides pharmaceutically useful transdermal flux rates over time.

Transdermal preparation contacting a loratidine metabolite with antihistaminic activity

The invention relates to a transdermal system containing at least one angiotensin-converting enzyme inhibitor.

Transdermally administrable medicament with ACE inhibitors

Pharmaceutical compositions containing enolic carboxamide type antiinflammatory agent meloxicam that exhibit improved wettability, aqueous solubility, dissolution behaviour over a broad range of pH, and that are prepared by crystal structure modification of the drug through dry or wet mechanical homogenization with two further components&mdash;one of them is selected from a group of oligo&mdash;and dissolution improving, or alkalizing agent. The application of the formulations according to the present invention results in an improved biovailability and effectiveness of meloxicam.

Pharmaceutical compositions of meloxicam with improved solubility and bioavailability

Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient

A pharmaceutical formulation comprising a benzimidazole derivative as active ingredient, and as excipients, at least one cyclodextrin and at least one amino acid.

Pharmaceutical antacid

Non-deliquescent formulation comprising or consisting of sodium valproate and cyclodextrin having a molar ratio of sodium valproate to cyclodextrin within the range of from 1:0.01 to 1:0.09.

Solid, non-deliquescent formulations of sodium valproate

Transdermal preparation containing a loratidine metabolite with

The invention relates to a pharmaceutical composition consisting of or containing cyclosporin A and .alpha.-tocopherol or one of the derivatives thereof.

Pharmaceutical composition containing cyclosporin A

Tablet or capsule having a content of stable ranitidine hydrochloride

A transdermal system in the form of a patch that comprises a tamoxifen derivative and an absorption-promoting additive for systemic administration.

Growing community of inventors

Holzkirchen, Germany

Karin Klokkers